Key Highlights

  • MedPal AI shares rose 5.26% to 4p, partially recovering from an April 2026 low of 2.15p.
  • Annualised Recurring Revenue reached £8.6m in July 2026, up from zero nine months earlier.
  • NHS dispensing hit a monthly record of 47,223 items, with private GLP-1 prescriptions adding a fast-growing revenue stream.
  • Cash fell to just £4,189 at the last balance-sheet date, underlining continued reliance on fundraising.
  • The share count rose from about 433.6m to 778m between January and August 2026, close to an 80% increase.

MedPal AI has gone from a pre-revenue AIM newcomer to an £8.6m revenue run-rate online pharmacy in under a year — but a wafer-thin cash balance and relentless share issuance keep the risks in plain view.

A volatile micro-cap back in the spotlight

MedPal AI plc (LSE:MPAL) rose 5.26% to 4p on 20 August 2026, valuing the London-listed micro-cap at roughly £31m. There was no single company announcement on the day that obviously accounts for the move; the shares have been volatile since flotation, and the latest gain came in a session where investors continued to weigh a Business that has reinvented itself at speed.

From a September 2025 high of 12.25p the stock had more than halved by an April low of 2.15p, so recent trading looks as much like a partial recovery from depressed levels as a fresh re-rating. With the name carrying the fashionable "AI" label and the company operating in the crowded digital-health space, MedPal is exactly the kind of speculative small cap that draws bursts of attention when sentiment towards the theme improves.

What MedPal actually does

Despite the "AI" in its name and ticker, MedPal's revenue today comes overwhelmingly from dispensing medicines, not from software. The company listed on AIM on 26 August 2025 describing itself as a "vertically integrated AI-powered digital health and pharmacy services company", and also carries a secondary Frankfurt listing under the ticker Z1N.

Its consumer-facing pitch — a non-clinical wellness app that aggregates data from Apple Health, Fitbit, Garmin and Google Fit and, since June 2026, an AI "health companion" called Juno — sits alongside the part of the group that actually generates cash: an online pharmacy dispensing NHS and private prescriptions, with a heavy tilt towards GLP-1 weight-loss and diabetes treatments supplied under agreements with Eli Lilly and Novo Nordisk. It is the pharmacy, led by chief executive Jason Drummond, rather than the app, that carries the near-term story.

Latest developments

Recent regulatory news captures the transformation. In a July trading update published on 4 August 2026, the company said annualised recurring revenue had reached £8.6m, describing the journey as "from zero to £8.6 million in nine months". NHS dispensing hit a monthly record of 47,223 items in July, worth more than £5.5m annualised, while private prescriptions — largely GLP-1 treatment plans routed through a New Health clinic — generated over £180,000 in the month, or £2.2m-plus annualised.

The 20 July Acquisition of eMARx, a care-home medication software business, adds roughly £0.843m of annualised software revenue at an 82% gross Margin and is the clearest genuine "AI/software" contributor so far. Earlier in the year MedPal bought Remedi pharmacy assets, signed an Eli Lilly Supply agreement, took its secondary Frankfurt listing and won a Care UK contract covering more than 200 care homes.

Financial and operational picture

The financials show a company scaling revenue fast while burning cash. For the year to 31 August 2025 MedPal reported no revenue and a pre-tax loss of about £4.0m, ending with £1.54m of cash — essentially a start-up that had only just floated. By the half-year to 28 February 2026 revenue had reached £1.6m, but the operating loss widened to £3.43m and the cash balance had collapsed to just £4,189 at the period end, from £1.54m six months earlier.

That near-empty Balance Sheet underlines how dependent the company has been on continual fundraising. Management has guided to pharmacy-level EBITDA breakeven at around 80,000 dispensed items a month, which it expects to reach in the fourth quarter of 2026 — a target that, on July's 47,223 items, still requires volumes to roughly double.

Funding those ambitions has meant heavy dilution. Alongside its roughly £2m IPO, MedPal has tapped the market repeatedly: an at-the-market Facility that had raised £0.88m by January 2026, a WRAP retail offer and placing in March, a £3m placing in April and a £5m placing in July. The share count has ballooned accordingly, from about 433.6m shares in January 2026 to 778m by August — an increase of close to 80% in barely half a year. With only around 17% of the stock in public hands, Liquidity is thin and the register concentrated.

What could drive the shares next?

Several potential catalysts are visible, though none should be treated as certain. Continued month-on-month growth in dispensing volumes towards the 80,000-item breakeven threshold would be the most tangible; a clean update showing the pharmacy turning cash-generative could change the Investment case materially.

Cross-selling — moving NHS patients onto private services such as blood testing, the MedPal Health OS app and the Juno companion — is management's stated route to higher-margin revenue, and any evidence that the software layer is monetising rather than merely Marketing would help justify the "AI" framing. Broader momentum in GLP-1 demand, underscored by the UK's August authorisation of Eli Lilly's once-daily weight-loss pill, keeps MedPal's core market in the headlines, while further bolt-on acquisitions, following eMARx and Remedi, look plausible given the pace so far.

Risks investors should watch

The risks are substantial and specific. The most pressing is funding: with cash reported at just £4,189 at the last balance-sheet date and the business still lossmaking, MedPal remains reliant on raising fresh capital, and each raise so far has diluted existing holders. The gap between the "AI healthcare" narrative and a business whose income is dominated by prescription dispensing invites scepticism, and much of the current revenue depends on a small number of GLP-1 supply relationships and NHS reimbursement dynamics that could shift.

Margins in dispensing are thin, execution risk around integrating acquisitions is real, and the low free float amplifies share-price swings in both directions. Investors should also note that the top line, while growing quickly, is quoted largely on an annualised run-rate basis rather than audited full-year figures, which can flatter the apparent scale of the business.

Investor takeaway

MedPal has delivered a genuinely rapid commercial ramp, and the reported jump to an £8.6m revenue run-rate is a real change from the pre-revenue shell that floated a year ago. But the equally real picture is of a micro-cap that has been kept alive by near-continuous fundraising, with a cash balance that had run to almost nothing by February and a share count that keeps rising.

Whether the latest move marks the start of a durable recovery or another swing in a volatile chart will depend less on the AI branding than on two hard numbers investors can track: monthly dispensing volumes edging towards breakeven, and whether the next set of accounts shows cash being generated rather than consumed.